Related Experiment Video
Updated: Aug 5, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Integrated transcriptomic and functional analyses identify PRR7 as a therapeutic target that associated with
Wei Sun1, Yuheng Si2, Lu Hong3
1Department of Urology, The Fourth Affiliated Hospital of Anhui Medical University, 64 Chaohu North Road, Hefei, Anhui Province, China; Department of Urology, The Second Affiliated Hospital of Anhui Medical University, 678 Furong Road, Hefei, Anhui Province, China.
Background:
Docetaxel resistance represents a major therapeutic challenge in advanced prostate cancer. Despite extensive studies on drug efflux, apoptosis, and metabolic adaptation, the specific cellular states and molecular determinants that sustain resistance remain poorly understood.
Methods:
To delineate the cellular basis of chemoresistance, we integrated bulk RNA sequencing of docetaxel-resistant prostate cancer models with single-cell transcriptomic data from patient tumors. Resistance-associated gene signatures were projected onto a single-cell atlas to identify docetaxel-resistant associated cancer cells (DRACs). Candidate regulators were screened through cross-dataset analysis and validated using molecular, cellular, and organoid-based assays, with functional and signaling consequences evaluated across in vitro and in vivo systems.
Results:
Single-cell mapping revealed a distinct epithelial cluster characterized by enrichment of resistance-related transcriptional programs and extensive communication with stromal cells. Integrative analyses identified PRR7 as a consistently upregulated gene within DRACs and resistant cell lines. PRR7 amplification and co-alteration with PI3K-AKT and Wnt pathway components were observed in clinical datasets. Functional inhibition of PRR7 suppressed β-catenin signaling, reduced cell viability, and downregulated stemness markers in docetaxel-resistant cells and patient-derived organoids. These results support a functional association between PRR7 and Wnt/β-catenin-related maintenance of resistance.
Conclusion:
The study defines DRACs as a transcriptionally distinct subpopulation sustaining docetaxel tolerance and identifies PRR7 as a regulatory hub connecting genomic alterations, Wnt/β-catenin activation, and stem-like phenotypes. These findings provide a framework for understanding chemoresistance in prostate cancer and suggest PRR7-centered signaling as a potential target for therapeutic intervention.
Insights
Docetaxel resistance in prostate cancer is sustained by distinct cancer cells (DRACs). The study identifies PRR7 as a key regulator of this resistance, linking genomic changes to Wnt/β-catenin signaling and stem-like traits.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Docetaxel resistance is a significant obstacle in advanced prostate cancer treatment.
- The cellular states and molecular drivers of this resistance are not fully understood, despite research into drug efflux, apoptosis, and metabolic changes.
Purpose of the Study:
- To identify the specific cellular states and molecular determinants that contribute to docetaxel resistance in prostate cancer.
- To understand the mechanisms underlying chemoresistance and identify potential therapeutic targets.
Main Methods:
- Integrated bulk RNA sequencing of docetaxel-resistant prostate cancer models with single-cell transcriptomic data from patient tumors.
- Projected resistance-associated gene signatures onto a single-cell atlas to identify docetaxel-resistant associated cancer cells (DRACs).
- Validated candidate regulators using molecular, cellular, and organoid-based assays in vitro and in vivo.
Main Results:
- Identified a distinct epithelial cell cluster (DRACs) with enriched resistance-related transcriptional programs and stromal cell communication.
- PR domain containing 7 (PRR7) was consistently upregulated in DRACs and resistant cell lines, with amplification and co-alteration in clinical datasets.
- PRR7 inhibition suppressed Wnt/β-catenin signaling, reduced cell viability, and decreased stemness markers in resistant cells and organoids.
Conclusions:
- DRACs represent a transcriptionally distinct subpopulation that maintains docetaxel tolerance in prostate cancer.
- PRR7 acts as a regulatory hub, connecting genomic alterations, Wnt/β-catenin activation, and stem-like phenotypes.
- Targeting PRR7-centered signaling presents a potential therapeutic strategy for overcoming docetaxel resistance in prostate cancer.
Related Concept Videos
Canonical Wnt Signaling Pathway
Non-Canonical Wnt Signaling Pathways
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

